WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018141002) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/141002 International Application No.: PCT/AU2018/000011
Publication Date: 09.08.2018 International Filing Date: 01.02.2018
IPC:
C07D 471/04 (2006.01) ,A61K 31/437 (2006.01) ,A61K 31/506 (2006.01) ,A61P 35/00 (2006.01)
Applicants: UNIVERSITY OF SOUTH AUSTRALIA[AU/AU]; North Terrace Adelaide, S.A. 5000, AU
Inventors: WANG, Shudong; AU
AL HAJ DIAB, Sarah; AU
LONG, Yi; AU
Agent: MADDERNS PATENT & TRADE MARK ATTORNEYS; GPO Box 2752 Adelaide, S.A. 5001, AU
Priority Data:
201790029001.02.2017AU
Title (EN) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
(FR) DÉRIVÉS DE N-CYCLOALKYL/HÉTÉROCYCLOALKYLE-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE EN TANT QU'AGENTS THÉRAPEUTIQUES
Abstract: front page image
(EN) A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).
(FR) L'invention concerne une nouvelle classe d'inhibiteurs de protéines kinases qui sont utiles dans le traitement de maladies et d'états pathologiques associés à la prolifération cellulaire, et notamment ceux caractérisés par une surexpression d'une ou plusieurs enzymes CDK et/ou l'activité aberrante d'une ou plusieurs CDK, notamment certains cancers des poumons, du sein, du cerveau, des ovaires, de la prostate, le cancer colorectal et les leucémies. Les inhibiteurs répondent à la formule générale (I).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)